SR-18292 is a compound that has garnered attention for its potential therapeutic applications, particularly in the field of metabolic disorders and cancer research. It functions as a selective inhibitor of the transcriptional coactivator PGC-1α, which plays a crucial role in regulating energy metabolism. By modulating PGC-1α activity, SR-18292 has shown promise in reducing hepatic glucose production, making it a candidate for the treatment of type 2 diabetes. Additionally, its ability to influence metabolic pathways has led to investigations into its potential for targeting cancer cells, which often rely on altered metabolism for growth and survival. Research is ongoing to explore its efficacy and safety in these areas.